 Active single agents in head and neck squamous cell carcinoma include methotrexate, bleomycin, cisplatin, carboplatin, 5-FU, paclitaxel, docetaxel, and CPT-11. A small randomized study showed that cisplatin monotherapy prolongs survival compared with best supportive care 5. Response rates for single agents range between 10-40 2, 4, 6, 7. Combination chemotherapy with platinum agents, in spite of achieving higher response rates about 30 in phase III trials, has not been shown to produce a survival benefit compared to single agents in randomized comparisons in recurrentmetastatic head and neck cancer 2, 4. 